December, 2015    SMM-137

The Future of Pfizer(s)

The media is full of the Pfizer-Allergan deal, especially the likely break up of the post-merger company into ‘innovative’ and ‘mature’ products. But lacking in this frenzied coverage is any sort of scientific examination of the move, which is ironic for an industry that prides itself on its knowledge intensity. This article offers an evolutionary science perspective on where that megadeal leads.